2018 Radford Long-Term Incentive
Practices Report for Life Sciences Companies

Overview

Developing a competitive long-term incentive program with the capacity to evolve and scale with your business is no easy task. This is particularly true in the life sciences sector, where market volatility and the ups and downs of drug development can swiftly change the fortunes of any organization in minutes. To support life sciences companies in dealing with these challenges, our new report provides an unparalleled data-driven view of the current equity compensation landscape across all employee levels and company types within the sector.

The cost to purchase this ground-breaking study, including comprehensive data from 169 pre-commercial and 109 commercial companies, is $2,500.

    Buy Now           Learn More  

What's covered in this study?

The 2018 Radford Long-Term Practices Report for Life Sciences Companies provides critical insights into topics like equity eligibility and participation rates, equity vehicle prevalence and mix by employee level, vesting schedules, aggregate equity spend and more. The table of contents includes:

Images shown are for illustrative purposes only and may not reflect actual data.